Current Heart Failure Reports最新文献_第9页

Cardiac CT Beyond Coronaries: Focus on Structural Heart Disease. 冠状动脉以外的心脏CT:关注结构性心脏病。

IF 3.8

Current Heart Failure Reports Pub Date : 2023-12-01 Epub Date: 2023-11-29 DOI: 10.1007/s11897-023-00635-9

Michaela M Hell, Tilman Emrich, Philipp Lurz, Ralph Stephan von Bardeleben, Axel Schmermund

{"title":"Cardiac CT Beyond Coronaries: Focus on Structural Heart Disease.","authors":"Michaela M Hell, Tilman Emrich, Philipp Lurz, Ralph Stephan von Bardeleben, Axel Schmermund","doi":"10.1007/s11897-023-00635-9","DOIUrl":"10.1007/s11897-023-00635-9","url":null,"abstract":"Purpose of review: Cardiac computed tomography (CT) is an established non-invasive imaging tool for the assessment of coronary artery disease. Furthermore, it plays a key role in the preinterventional work-up of patients presenting with structural heart disease.Recent findings: CT is the gold standard for preprocedural annular assessment, device sizing, risk determination of annular injury, coronary occlusion or left ventricular outflow tract obstruction, calcification visualization and quantification of the target structure, and prediction of a co-planar fluoroscopic angulation for transcatheter interventions in patients with structural heart disease. It is further a key imaging modality in postprocedural assessment for prosthesis thrombosis, degeneration, or endocarditis. CT plays an integral part in the imaging work-up of novel transcatheter therapies for structural heart disease and postprocedural assessment for prosthesis thrombosis or endocarditis. This review provides a comprehensive overview of the key role of CT in the context of structural heart interventions.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"484-492"},"PeriodicalIF":3.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10746749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138451146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Your Heart Function Has Normalized-What Next After TRED-HF? 你的心脏功能已经恢复正常——在接受了心脏病治疗后，下一步该怎么办?

IF 3.8

Current Heart Failure Reports Pub Date : 2023-12-01 Epub Date: 2023-11-24 DOI: 10.1007/s11897-023-00636-8

Alexandros Kasiakogias, Aaraby Ragavan, Brian P Halliday

{"title":"Your Heart Function Has Normalized-What Next After TRED-HF?","authors":"Alexandros Kasiakogias, Aaraby Ragavan, Brian P Halliday","doi":"10.1007/s11897-023-00636-8","DOIUrl":"10.1007/s11897-023-00636-8","url":null,"abstract":"Purpose of review: With the widespread implementation of contemporary disease-modifying heart failure therapy, the rates of normalization of ejection fraction are continuously increasing. The TRED-HF trial confirmed that heart failure remission rather than complete recovery is typical in patients with dilated cardiomyopathy who respond to therapy. The present review outlines key points related to the management and knowledge gaps of this growing patient group, focusing on patients with non-ischaemic dilated cardiomyopathy.Recent findings: There is substantial heterogeneity among patients with normalized ejection fraction. The specific etiology is likely to affect the outcome, although a multiple-hit phenotype is frequent and may not be identified without comprehensive characterization. A monogenic or polygenic genetic susceptibility is common. Ongoing pathophysiological processes may be unraveled with advanced cardiac imaging, biomarkers, multi-omics, and machine learning technologies. There are limited studies that have investigated the withdrawal of specific heart failure therapies in these patients. Diuretics may be safely withdrawn if there is no evidence of congestion, while continued therapy with at least some disease-modifying therapy is likely to be required to reduce myocardial workload and sustain remission for the vast majority. Understanding the underlying disease mechanisms of patients with normalized ejection fraction is crucial in identifying markers of myocardial relapse and guiding individualized therapy in the future. Ongoing clinical trials should inform personalized approaches to therapy.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"542-554"},"PeriodicalIF":3.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10746577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138298595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Right Heart in Congenital Heart Disease. 先天性心脏病的右心。

Current Heart Failure Reports Pub Date : 2023-12-01 Epub Date: 2023-09-29 DOI: 10.1007/s11897-023-00629-7

Alexandra Arvanitaki, Gerhard Diller, George Giannakoulas

{"title":"The Right Heart in Congenital Heart Disease.","authors":"Alexandra Arvanitaki, Gerhard Diller, George Giannakoulas","doi":"10.1007/s11897-023-00629-7","DOIUrl":"10.1007/s11897-023-00629-7","url":null,"abstract":"Purpose of review: To analyze the pathophysiologic importance of the right heart in different types of congenital heart disease (CHD), summarize current diagnostic modalities, and discuss treatment options.Recent findings: The right ventricle (RV) plays a key role in disease progression and prognosis, either as the subpulmonary or as the systemic ventricle. Volume and/or pressure overload as well as intrinsic myocardial disease are the main factors for RV remodeling. Echocardiography and cardiac magnetic resonance imaging are important noninvasive modalities for assessing anatomy, size, and function of the right heart. Timely repair of related lesions is essential for preventing RV dysfunction. Few inconclusive data exist on conventional pharmacotherapy in CHD-related RV dysfunction. Cardiac resynchronization therapy and ventricular assist devices are an option in patients with advanced systemic RV failure. Right heart disease is highly related with adverse clinical outcomes in CHD. Research should focus on early identification of patients at risk and development of medical and interventional treatments that improve RV function.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"471-483"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41125642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coordinated Metabolic Responses Facilitate Cardiac Growth in Pregnancy and Exercise. 协调的代谢反应促进怀孕和运动中的心脏生长。

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-08-15 DOI: 10.1007/s11897-023-00622-0

Emily B Schulman-Geltzer, Helen E Collins, Bradford G Hill, Kyle L Fulghum

{"title":"Coordinated Metabolic Responses Facilitate Cardiac Growth in Pregnancy and Exercise.","authors":"Emily B Schulman-Geltzer, Helen E Collins, Bradford G Hill, Kyle L Fulghum","doi":"10.1007/s11897-023-00622-0","DOIUrl":"10.1007/s11897-023-00622-0","url":null,"abstract":"Purpose of review: Pregnancy and exercise are systemic stressors that promote physiological growth of the heart in response to repetitive volume overload and maintenance of cardiac output. This type of remodeling is distinct from pathological hypertrophy and involves different metabolic mechanisms that facilitate growth; however, it remains unclear how metabolic changes in the heart facilitate growth and if these processes are similar in both pregnancy- and exercise-induced cardiac growth.Recent findings: The ability of the heart to metabolize a myriad of substrates balances cardiac demands for energy provision and anabolism. During pregnancy, coordination of hormonal status with cardiac reductions in glucose oxidation appears important for physiological growth. During exercise, a reduction in cardiac glucose oxidation also appears important for physiological growth, which could facilitate shuttling of glucose-derived carbons into biosynthetic pathways for growth. Understanding the metabolic underpinnings of physiological cardiac growth could provide insight to optimize cardiovascular health and prevent deleterious remodeling, such as that which occurs from postpartum cardiomyopathy and heart failure. This short review highlights the metabolic mechanisms known to facilitate pregnancy-induced and exercise-induced cardiac growth, both of which require changes in cardiac glucose metabolism for the promotion of growth. In addition, we mention important similarities and differences of physiological cardiac growth in these models as well as discuss current limitations in our understanding of metabolic changes that facilitate growth.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"441-450"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10353703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis. 利钠肽和心脏肌钙蛋白：轻链心脏淀粉样变性疾病进展和风险的标志物。

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-07-10 DOI: 10.1007/s11897-023-00616-y

Isabel Wees, Nicholas S Hendren, Gurbakhash Kaur, Lori R Roth, Justin L Grodin

{"title":"Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis.","authors":"Isabel Wees, Nicholas S Hendren, Gurbakhash Kaur, Lori R Roth, Justin L Grodin","doi":"10.1007/s11897-023-00616-y","DOIUrl":"10.1007/s11897-023-00616-y","url":null,"abstract":"Purpose of review: Light chain (AL) amyloidosis can cause an infiltrative cardiomyopathy that can result in symptomatic heart failure. The vague, nonspecific onset of signs and symptoms may lead to a delay in diagnosis and treatment leading to poor outcomes. Cardiac biomarkers, such as troponins and natriuretic peptides, play a pivotal role in diagnosis, determining prognosis, and assessing treatment response in patients with AL amyloidosis. Because of the evolving landscape for both diagnosis and treatment of AL cardiac amyloidosis, we review the critical role these and other biomarkers play in the clinical management of this disease.Recent findings: A number of conventional cardiac and noncardiac serum biomarkers are commonly used in AL cardiac amyloidosis and may be surrogates for cardiac involvement and inform prognosis. These include typical heart failure biomarkers such as levels of circulating natriuretic peptides as well as cardiac troponins. Other noncardiac biomarkers frequently measured in AL cardiac amyloidosis included difference between the involved and uninvolved free light chains (dFLC) and markers of endothelial cell activation and damage such as von Willebrand factor antigen and matrix metalloproteinases. AL amyloidosis can lead to cardiac involvement which has been associated with poor outcomes, especially if not identified and treated early. Natriuretic peptides and cardiac troponins are cornerstones for the diagnosis and management of AL cardiac amyloidosis. Their levels may represent cardiac stress, injury, and possibly degree of cardiac involvement, and they play a key role in AL amyloidosis disease staging.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"350-357"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure. 利钠肽受体（NPRs）作为治疗心力衰竭的潜在靶点。

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-09-15 DOI: 10.1007/s11897-023-00628-8

Adamu T Bekele

{"title":"Natriuretic Peptide Receptors (NPRs) as a Potential Target for the Treatment of Heart Failure.","authors":"Adamu T Bekele","doi":"10.1007/s11897-023-00628-8","DOIUrl":"10.1007/s11897-023-00628-8","url":null,"abstract":"Purpose of review: Heart failure is defined as a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood. The natriuretic peptide is known to exert its biological action on the kidney, heart, blood vessels, renin-angiotensin system, autonomous nervous system, and central nervous system. The natriuretic peptide-natriuretic receptor system plays an important role in the regulation of blood pressure and body fluid volume through its pleiotropic effects.Recent findings: The clinical and animal studies suggest that natriuretic peptide-natriuretic receptors are important targets for the treatment of heart failure and other cardiovascular diseases. Even though attempts targeting natriuretic peptide receptors are underway for heart failure treatment, they seem insufficient despite the receptor systems' potential. This review summarizes natriuretic peptide-natriuretic receptor system's physiological actions and potential target for the treatment of heart failure. Natriuretic peptides play multiple roles in different parts of the body, almost all of the activities related to this receptor system appear to have the potential to be harnessed to treat heart failure or symptoms associated with heart failure.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"429-440"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10608967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Failure in the Elderly: the Role of Biological and Sociocultural Aspects Related to Sex. 老年人心力衰竭：与性别相关的生物学和社会文化方面的作用。

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-07-27 DOI: 10.1007/s11897-023-00619-9

Pablo Díez-Villanueva, César Jiménez-Méndez, María Thiscal López-Lluva, Samantha Wasniewski, Jorge Solís, Leticia Fernández-Friera, Manuel Martínez-Sellés

{"title":"Heart Failure in the Elderly: the Role of Biological and Sociocultural Aspects Related to Sex.","authors":"Pablo Díez-Villanueva, César Jiménez-Méndez, María Thiscal López-Lluva, Samantha Wasniewski, Jorge Solís, Leticia Fernández-Friera, Manuel Martínez-Sellés","doi":"10.1007/s11897-023-00619-9","DOIUrl":"10.1007/s11897-023-00619-9","url":null,"abstract":"Purpose of review: Heart failure (HF) entails poor prognosis, with high morbidity and mortality burden, particularly in elderly patients. Notably, important sex differences have been described between men and women with HF. In this regard, some biological and sociocultural aspects related to sex may play a key role in the different development and prognosis of HF in elderly men and women.Recent findings: Important differences between men and women with HF, especially in the elderly population, have been specifically addressed in recent studies. Consequently, specific differences in biological and sociocultural aspects have been found to associate differences in pathophysiology, baseline clinical profile, and prognosis according to sex. Moreover, differences in comorbidities and frailty and other geriatric conditions, frequent in elderly population with HF, have also been described. Biological and sociocultural differences related to sex are key in the different clinical presentation and prognosis of heart failure in elderly women. Further studies will be required to better understand some other underlying reasons that may differently impact prognosis in elderly patients with HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"321-332"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9876836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mechanism of COVID-19-Induced Cardiac Damage from Patient, In Vitro and Animal Studies. COVID-19导致的患者心脏损伤的机制、体外和动物研究。

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-08-01 DOI: 10.1007/s11897-023-00618-w

Elizabeth A V Jones

{"title":"Mechanism of COVID-19-Induced Cardiac Damage from Patient, In Vitro and Animal Studies.","authors":"Elizabeth A V Jones","doi":"10.1007/s11897-023-00618-w","DOIUrl":"10.1007/s11897-023-00618-w","url":null,"abstract":"Purpose of review: Though patient studies have been important for understanding the disease, research done in animals and cell culture complement our knowledge from patient data and provide insight into the mechanism of the disease. Understanding how COVID causes damage to the heart is essential to understanding possible long-term consequences.Recent findings: COVID-19 is primarily a disease that attacks the lungs; however, it is known to have important consequences in many other tissues including the heart. Though myocarditis does occur in some patients, for most cases of cardiac damage, the injury arises from scarring either due to myocardial infarction or micro-infarction. The main focus is on how COVID affects blood flow through the coronaries. We review how endothelial activation leads to a hypercoagulative state in COVID-19. We also emphasize the effects that the cytokine storm can directly have on the regulation of coronary blood flow. Since the main two cell types that can be infected in the heart are pericytes and cardiomyocytes, we further describe the known effects on pericyte function and how that can further lead to microinfarcts within the heart. Though many of these effects are systemic, this review focuses on the consequences on cardiac tissue of this dysregulation and the role that it has in the formation of myocardial scarring.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"451-460"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9912118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perspectives on Secondary Mitral Regurgitation in Heart Failure. 心力衰竭继发性二尖瓣反流的研究进展。

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-09-11 DOI: 10.1007/s11897-023-00627-9

Theo E Meyer, Kai Chen, Matthew W Parker, Jeff Shih, Youssef Rahban

{"title":"Perspectives on Secondary Mitral Regurgitation in Heart Failure.","authors":"Theo E Meyer, Kai Chen, Matthew W Parker, Jeff Shih, Youssef Rahban","doi":"10.1007/s11897-023-00627-9","DOIUrl":"10.1007/s11897-023-00627-9","url":null,"abstract":"Purpose of the review: This review focuses on broader perspectives of mitral regurgitation (MR) in patients with heart failure.Recent findings: The ratio of regurgitant volume to end-diastolic volume appears to help identify patients who may benefit from valve interventions. Secondary MR is not only attributed to geometric changes of the LV but also related to the structural changes in the mitral valve that include fibrosis of the mitral leaflets and changes in the extracellular matrix. The transition from mild to severe secondary MR can occur at different rates, from a slow LV remodeling process to a more abrupt process precipitated by an inciting event such as atrial fibrillation. Septal flash and apical rocking, two new visual markers of LV mechanical dyssynchrony, appear to be predictive of MR reduction following cardiac resynchronization therapy. Optimal guideline-directed medical therapy has been shown to decrease the severity of secondary MR effectively. A theoretical framework to characterize secondary MR as it relates to the onset of MR is proposed. Type A: Early onset of MR contemporaneous with myocardial injury. The maladaptive LV remodeling occurs in parallel with MR. Type B: LV remodeling proceeds without significant MR until the LV is moderately dilated, which coincides with or without inciting factors such as atrial fibrillation. Type C: LV remodeling proceeds after myocardial injury without significant MR until the LV is severely dilated. MR is a late manifestation of LV remodeling.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"417-428"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10202887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies. 心力衰竭的多发病率：利用聚类分析指导量身定制的治疗策略。

IF 3.4

Current Heart Failure Reports Pub Date : 2023-10-01 Epub Date: 2023-09-02 DOI: 10.1007/s11897-023-00626-w

Mariëlle C van de Veerdonk, Gianluigi Savarese, M Louis Handoko, Joline W J Beulens, Folkert Asselbergs, Alicia Uijl

{"title":"Multimorbidity in Heart Failure: Leveraging Cluster Analysis to Guide Tailored Treatment Strategies.","authors":"Mariëlle C van de Veerdonk, Gianluigi Savarese, M Louis Handoko, Joline W J Beulens, Folkert Asselbergs, Alicia Uijl","doi":"10.1007/s11897-023-00626-w","DOIUrl":"10.1007/s11897-023-00626-w","url":null,"abstract":"Review purpose: This review summarises key findings on treatment effects within phenotypical clusters of patients with heart failure (HF), making a distinction between patients with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF).Findings: Treatment response differed among clusters; ACE inhibitors were beneficial in all HFrEF phenotypes, while only some studies show similar beneficial prognostic effects in HFpEF patients. Beta-blockers had favourable effects in all HFrEF patients but not in HFpEF phenotypes and tended to worsen prognosis in older, cardiorenal patients. Mineralocorticoid receptor antagonists had more favourable prognostic effects in young, obese males and metabolic HFpEF patients. While a phenotype-guided approach is a promising solution for individualised treatment strategies, there are several aspects that still require improvements before such an approach could be implemented in clinical practice. Stronger evidence from clinical trials and real-world data may assist in establishing a phenotype-guided treatment approach for patient with HF in the future.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"461-470"},"PeriodicalIF":3.4,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10589138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10148366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0